The medical community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s showing significant promise in clinical trials for treating obesity. Unlike some current weight loss approaches, retatrutide appears to deliver a greater substantial decrease in body size and improve metabolic function, particu